Patient care standards for primary mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society

Type of publication: Consensus-based statements
Disease: Mitochondrial disease

Authors:

Sumit Parikh, Amy Goldstein, Amel Karaa, Mary Kay Koenig, Irina Anselm, Catherine Brunel-Guitton, John Christodoulou, Bruce H Cohen, David Dimmock, Gregory M Enns, Marni J Falk, Annette Feigenbaum, Richard E Frye, Jaya Ganesh, David Griesemer, Richard Haas, Rita Horvath, Mark Korson, Michael C Kruer, Michelangelo Mancuso, Shana McCormack, Marie Josee Raboisson, Tyler Reimschisel, Ramona Salvarinova, Russell P Saneto, Fernando Scaglia, John Shoffner, Peter W Stacpoole, Carolyn M Sue, Mark Tarnopolsky, Clara Van Karnebeek, Lynne A Wolfe, Zarazuela Zolkipli Cunningham, Shamima Rahman, Patrick F Chinnery


The purpose of this statement is to provide consensus-based recommendations for optimal management and care for patients with primary mitochondrial disease. This statement is intended for physicians who are engaged in the diagnosis and management of these patients. Working group members were appointed by the Mitochondrial Medicine Society. The panel included members with several different areas of expertise. The panel members utilized surveys and the Delphi method to reach consensus. We anticipate that this statement will need to be updated as the field continues to evolve. Consensus-based recommendations are provided for the routine care and management of patients with primary genetic mitochondrial disease.


Published: 27 July 2017
Journal: Genetics in Medicine, volume 19, issue 12, pages 1380

Link: doi.org/10.1038/gim.2017.107

The ERNs are co-funded by the
European Union (Health Programme and CEF)

EU Commission

“EURO-NMD is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are co-funded by the European Union (Health Programme and CEF).
For more information about the ERNs and the EU health strategy,
please visit ec.europa.eu/health/ern